Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf213 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Satı Coşkun Yazgan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara University School of Medicine, Ankara 06620, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring, Androgen Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Prostate-specific membrane antigen (PSMA) is a key target in metastatic castration resistance prostate cancer (mCRPC). Enzalutamide, an androgen receptor pathway inhibitor (ARPi), increases PSMA expression, potentially enhancing 177Lu-PSMA-617 radioligand therapy. This study evaluates the impact of prior ARPi (enzalutamide vs abiraterone acetate [AA]) on PSMA expression, PFS, and OS. Materials and Methods A retrospective analysis of 214 mCRPC patients treated with 177Lu-PSMA-617 across six Turkish centers (2015-2025) was conducted. Patients were grouped by prior ARPi therapy. PFS and OS were analyzed using Kaplan-Meier and Cox regression methods.
Results
Among 103 patients receiving ARPi before 177Lu-PSMA-617, 59 (57%) had enzalutamide and 44 (43%) AA. Median PFS was 7.6 months for enzalutamide versus 5.3 months for AA (P = .068). Median OS was significantly longer with enzalutamide (12.8 vs 6.9 months, P = .021). Patients with Eastern Cooperative Oncology Group Performance Scores (ECOG PS) 0-1 had significantly longer OS (27.6 vs 6.9 months for PS 2-3, P < .0001). Higher PSMA SUVmax (>20) correlated with longer OS (15.1 vs 7.8 months, P = .016). Among 86 patients with detectable PSMA SUVmax, 53 had SUVmax > 20; 66% had prior enzalutamide and 34% AA. Median OS was four months longer with enzalutamide (18.1 vs 13.9 months P = .120). Multivariate analysis identified ARPi type (HR: 2.24, P = .033) and ECOG PS (HR: 5.22, P < .0001) as independent OS predictors.
Conclusion
Enzalutamide prior to 177Lu-PSMA-617 significantly improves OS and enhances PSMA expression compared to AA. These findings highlight the importance of treatment sequencing in mCRPC and warrant further prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Ankara University School of Medicine, Ankara 06620, Turkey.
- Ankara University Cancer Institute, Ankara, 06620, Turkey.
- Department of Medical Oncology, Gaziantep University School of Medicine, Gaziantep 27310, Turkey.
- Department of Medical Oncology, Izmir University of Economics, Medical Point Hospital, Izmir 35330, Turkey.
- Department of Medical Oncology, Koç University School of Medicine, Istanbul 34010, Turkey.
- Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Health Sciences University, Ankara 06200, Turkey.
Zitieren
APA
Yazgan, S. C., Kayaş, K., Arslan, Ç., Kapar, C., Öztekin, Ş., Ceylan, F., Bölek, H., Elboğa, U., Ateş, Ö., Tural, D., Kuş, T., Şendur, M. A. N., Yekedüz, E., Küçük, N. Ö., Çıngı Özdemir, E., & Ürün, Y. (2025). Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy. The Oncologist. https://doi.org/10.1093/oncolo/oyaf213
Vancouver
Yazgan SC, Kayaş K, Arslan Ç, Kapar C, Öztekin Ş, Ceylan F, et al. Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy. The Oncologist. 2025. doi:10.1093/oncolo/oyaf213
BibTeX
@article{Yazgan2025,
author = {Yazgan, Satı Coşkun and Kayaş, Kamil and Arslan, Çağatay and Kapar, Caner and Öztekin, Şura and Ceylan, Furkan and Bölek, Hatice and Elboğa, Umut and Ateş, Öztürk and Tural, Deniz and Kuş, Tülay and Şendur, Mehmet Ali Nahit and Yekedüz, Emre and Küçük, Nuriye Özlem and Çıngı Özdemir, Elif and Ürün, Yüksel},
title = {Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf213}
}
EUVIMED